Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of
idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of …

Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess
efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant …

Oxaliplatin-based chemotherapy is a standard treatment approach for colorectal cancer
(CRC). However, oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe dose …

Background The combination of aflibercept with FOLFIRI has been shown to significantly
prolong overall survival in patients with metastatic colorectal cancer (mCRC) after …

Background Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis.
Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase …

Background Recently, the immunostimulatory roles of chemotherapeutics have been
increasingly revealed, although bone marrow suppression is still a common toxicity of …

Introduction: Anti-angiogenetic agents are currently the standard of care in metastatic CRC
patients. Bevacizumab, aflibercept, regorafenib and recently ramucirumab have significantly …

Introduction: Angiogenesis is a complex process regulated by several pro-and anti-
angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer …

Background: Metastatic CRC (mCRC) is a molecular heterogeneous disease. The aim of
this review is to give an overview of molecular-driven treatment of mCRC patients. Methods …